SCHEMBL2977409

SCHEMBL2977409

Cc1nc(Cl)sc1S(=O)(=O)NC1CCS(=O)(=O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.38
HPGD P15428 2/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA5A P35218 1/20 0.37
CA9 Q16790 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
IKBKB O14920 9/20 0.36
CHUK O15111 9/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 3/20 0.34
MAPK1 P28482 1/20 0.34
GLP1R P43220 1/20 0.34
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7252974 0.89 CA12 (0.43) HPGDCA12CA1CA2CA5A
SCHEMBL2977405 0.88 CA12 (0.39) HSD17B10HPGDCA12CA1CA2
SCHEMBL6621823 0.71 ALDH1A1 (0.40) HPGDCA12CA1CA2CA5A
SCHEMBL1177587 0.69 ALDH1A1 (0.44) HPGDKMT2AALDH1A1
SCHEMBL2994739 0.66 IKBKB (0.51) IKBKBCHUKKMT2AMAPK1ALDH1A1
SCHEMBL1177539 0.65 ALDH1A1 (0.44) HPGDCA12CA1CA2CA5A
SCHEMBL13013467 0.65 ALDH1A1 (0.69) HPGDIKBKBCHUKCYP3A4KMT2A
SCHEMBL13981373 0.65 SMN1; SMN2 (0.53) HSD17B10HPGDIKBKBCHUKKMT2A
SCHEMBL2988057 0.65 HPGD (0.53) HSD17B10HPGDIKBKBCHUKKMT2A
SCHEMBL2823087 0.64 ALDH1A1 (0.47) HPGDKMT2AALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179139-A1 PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS BAMBOROUGH PAUL 2010-07-15 US disclosed
US-20100179139-A1 PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS BAMBOROUGH PAUL 2010-07-15 US disclosed
US-20100179139-A1 PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS BAMBOROUGH PAUL 2010-07-15 US disclosed
WO-2008145688-A2 PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS GLAXO GROUP LIMITED (GB) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179139-A1 PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS NFKBIA, PACSIN2, MAP3K2 HSD17B10 3783/4885HPGD 930/4885CA12 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.